



**TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION
(COMISIÓN NACIONAL DEL MERCADO DE VALORES)**

Madrid, 27 February 2024

In compliance with the reporting requirements provided for in article 226 of the Consolidated Text of the Securities Market Act, Laboratorios Farmacéuticos Rovi, S.A. (hereinafter, “**ROVI**” or the “**Company**”) hereby discloses to the Spanish National Securities Market Commission (“**CNMV**”) the following

INSIDE INFORMATION

The meeting of ROVI's Board of Directors held yesterday formally adopted, among others which do not modify them, the following resolutions:

- I. Drawing up of the individual annual accounts of the Company and consolidated annual accounts of ROVI Group and the respective management reports corresponding to fiscal year ended on 31 December 2023 (including, within the integrated report that is incorporated in the consolidated management report, the Non-Financial Information Statement as of that date), and propose to the General Meeting of Shareholders the distribution of a dividend against the results of fiscal year 2023 and the results from previous years in a gross amount of 1.1037 euros per share entitled to receive it (which would imply the distribution of an amount equivalent to approximately 35% of the consolidated net profit of year 2023 attributed to the parent company).
- II. Approval and disclosure, following a favourable report from the Audit Committee and the Appointments and Remunerations Committee, within their respective competences, the following reports corresponding to fiscal year 2023:
 - Annual Financial Report.
 - Annual Corporate Governance Report.
 - Annual Report on Remuneration of Directors.
 - Integrated Report (which includes the Non-financial Information Statement).

The abovementioned reports will likewise be available on the corporate web page (www.rovi.es).

Mr. Juan López-Belmonte Encina
President of the Board of Directors and CEO
Laboratorios Farmacéuticos ROVI, S.A.